ZEUS

Trial Overview

Official Title

Effects of ziltivekimab versus placebo on cardiovascular outcomes in patients with established atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation.

Study Purpose

An interventional, randomised, parallel-group, double-blind, placebo-controlled, multi-centre, multi-national CVOT designed to evaluate the effects of 15 mg ziltivekimab versus placebo (randomised 1:1), both administered s.c. once-monthly and added to standard of care, on CV outcomes in participants with established ASCVD, CKD and systemic inflammation.

Diagnosis

ASCVD, CKD and systemic inflammation.

Eligibility

ASCVD, CKD and systemic inflammation.

Intervention

ziltivekimab 15 mg/mL single-use pre-filled syringe (1 mL)
placebo single-use pre-filled syringe (1 mL)

For more information, visit clinicaltrials.gov.

Key Participation Requirements

Trial Location(s)

Methodist Physicians Clinic

Gender

All genders

Age

19 years or older

Enrollment Status

Recruiting

Phase

Phase III

Methodist Health System Trial Code

NCT05021835